Skip to main
ZBIO

ZBIO Stock Forecast & Price Target

ZBIO Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Zenas BioPharma is in a strong financial position with a reported net loss of $111.50MM in 2Q26. Their promising pipeline, including the potential blockbuster obexelimab, and a significant cash balance of $674MM give them a competitive edge, with continued platform advancement and upcoming catalysts in 2026 supporting an OUTPERFORM rating and PT of $45.

Bears say

Zenas BioPharma is facing risks to its future sales estimates, as there is no guarantee that their lead program will prove to be efficacious or have a desired dosing interval. Additionally, the company may face regulatory delays that could impact market uptake and financing requirements. There are also questions surrounding how Zenas will differentiate its oral CNS-penetrant BTK inhibitor from other therapies in development for primary progressive MS and non-active secondary progressive MS. The company's recent acquisition of in-process research and development for 10,000 also raises questions about their financial stability and ability to fund future developments.

ZBIO has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zenas Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zenas Biopharma Inc (ZBIO) Forecast

Analysts have given ZBIO a Buy based on their latest research and market trends.

According to 6 analysts, ZBIO has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zenas Biopharma Inc (ZBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.